Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

FMA orders compensation for Pacific Edge shareholders

Pacific Edge gets FMA warning over disclosure, must compensate shareholders

By Jonathan Underhill

May 25 (BusinessDesk) - Pacific Edge, which commercialised a non-invasive test for bladder cancer, has agreed to make a $500,000 compensation payment to shareholders after an investigation by the Financial Markets Authority found that the company probably breached NZX listing rules on continuous disclosure.

The regulator issued a public warning to Pacific Edge after investigating delays in disclosing new contracts in 2013. The compensation payment will go to shareholders who sold the stock in the window between the company signing the contracts and making an announcement to the NZX, the FMA said in a statement.

Pacific Edge shares soared as much as 250 percent in little more than a week following the company's October 2013 announcements that it had signed agreements with US national healthcare providers FedMed, American's Choice Provider Network and Stratose, making its Cxbladder test available to 40 million Americans. In acknowledging the historical breaches, the company said today that it had been contractually bound to get approval from its counterparties before making such an announcement which "led to a delay between signing of the agreements and the announcements to the NZX."

The stock reached as high as $1.637 on Oct. 23, 2013 and reached $1.76 in February 2014, only to give up much of its gains. It last traded at 73 cents.

The FMA said Pacific Edge can offer shareholders shares instead of cash as compensation. The compensation covers investors who sold the shares from 10am on Oct. 11 through until 10am on Oct. 18 that year, the FMA said. As a result of the investigation, the company has undertaken a compliance audit and has implemented the compliance recommendations, the regulator said.

"In determining the outcome, we took into account the specific factors of this case, including the nature of the conduct, Pacific Edge's offer of compensation to investors, and willingness to undertake the compliance audit," said Belinda Moffat, the FMA's director of enforcement and investigations.

(BusinessDesk)

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.